Supplementary Figure 5 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• ERBB2 alterations were identified in the ctDNA of patients with metastatic urothelial cancer, indicating a distinct genomic profile.
• Targeted sequencing unveiled significant findings, revealing critical insights into the molecular landscape of mUC.
• The analysis of ctDNA offers a non-invasive approach to understanding tumor genetics, enhancing patient management insights.
• These findings may enable future therapeutic strategies, calling for more comprehensive studies on ctDNA in urothelial cancer.